These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8330872)

  • 1. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study.
    Dörr U; Würstlin S; Frank-Raue K; Raue F; Hehrmann R; Iser G; Scholz M; Guhl L; Buhr HJ; Bihl H
    Horm Metab Res Suppl; 1993; 27():48-55. PubMed ID: 8330872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
    Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
    J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents.
    Lodish M; Dagalakis U; Chen CC; Sinaii N; Whitcomb P; Aikin A; Dombi E; Marcus L; Widemann B; Fox E; Chuk M; Balis F; Wells S; Stratakis CA
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E207-12. PubMed ID: 22162469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
    Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid.
    Dörr U; Sautter-Bihl ML; Bihl H
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):42-5. PubMed ID: 7992080
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma.
    Dörr U; Frank-Raue K; Raue F; Sautter-Bihl ML; Guzman G; Buhr HJ; Bihl H
    Nucl Med Commun; 1993 Jun; 14(6):439-45. PubMed ID: 8100624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
    Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
    Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).
    Kurtaran A; Leimer M; Kaserer K; Yang Q; Angelberger P; Niederle B; Virgolini I
    Nucl Med Biol; 1996 May; 23(4):503-7. PubMed ID: 8832707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan.
    Baudin E; Schlumberger M; Lumbroso J; Travagli JP; Caillou B; Parmentier C
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2541-4. PubMed ID: 8675574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
    Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
    Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma.
    Kurtaran A; Scheuba C; Kaserer K; Schima W; Czerny C; Angelberger P; Niederle B; Virgolini I
    J Nucl Med; 1998 Nov; 39(11):1907-9. PubMed ID: 9829581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Somatostatin receptor status in non-medullary thyroid carcinoma].
    Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
    Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging.
    Sarlis NJ; Gourgiotis L; Guthrie LC; Galen B; Skarulis MC; Shawker TH; Patronas NJ; Reynolds JC
    Clin Nucl Med; 2003 Mar; 28(3):208-17. PubMed ID: 12592128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
    Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
    Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution of 111In-pentetreotide and dosimetric considerations with respect to somatostatin receptor expressing tumor burden.
    Adrian HJ; Dörr U; Bach D; Bihl H
    Horm Metab Res Suppl; 1993; 27():18-23. PubMed ID: 8330868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies.
    Khanna G; O'Dorisio MS; Menda Y; Glasier C; Deyoung B; Smith BJ; Graham M; Juweid M
    Pediatr Blood Cancer; 2008 Mar; 50(3):561-6. PubMed ID: 17387742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
    Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I
    Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bronchial carcinoid tumor and scintigraphy of somatostatin receptors: detection of bone metastasis].
    Banzo J; Abós MD; Prats E; García F; Freile E; Razola P; Escalera T
    Rev Esp Med Nucl; 2001 Oct; 20(6):431-8. PubMed ID: 11578577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.
    Gotthardt M; Béhé MP; Grass J; Bauhofer A; Rinke A; Schipper ML; Kalinowski M; Arnold R; Oyen WJ; Behr TM
    Endocr Relat Cancer; 2006 Dec; 13(4):1203-11. PubMed ID: 17158765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.